Skip to search formSkip to main contentSkip to account menu

semapimod

Known as: N,N'-Bis(3,5-bis(1-(carbamimidoylhydrazono)ethyl)phenyl)decanediamide 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Anti-Inflammatory Agents, Non-SteroidalHydrazonesImmunosuppressive Agents

Narrower (1)

CNI 1493

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion.
Glioblastoma multiforme (grade IV glioma) is a very aggressive human cancer with a median survival of 1 year post diagnosis… 
2011
2011
Semapimod a new pretreatment modality of acute intestinal ischemia-reperfusion syndrome: experimental study in rabbits.
AIM Semapimod is an experimental drug that strongly inhibits macrophages and stimulates the cholinergic anti-inflammatory pathway… 
2009
2009
P38 MAPK inhibitor semapimod reduces postoperative ileus via peripheral and central mechanisms.
2009
2009
P38 MAPK Inhibitor Semapimod Reduces Postoperative Ileus Via Peripheral and Central Mechanisms
2007
2007
Prophylaxis of Post-ERCP Pancreatitis: A Randomized, Placebo Controlled Trial Using Intravenous Infusion of Semapimod, a Mitogen Activated Protein Kinases Inhibitor
2005
2005
Specific Inhibition of c-Raf Activity by Semapimod Induces Clinical Remission in Severe Crohn’s Disease1
There is a substantial need for novel treatment strategies in Crohn’s disease (CD), a chronic relapsing inflammatory disease of… 
2005
2005
Severe Crohn's Disease Semapimod Induces Clinical Remission in Specific Inhibition of c-Raf Activity by
There is a substantial need for novel treatment strategies in Crohn’s disease (CD), a chronic relapsing inflammatory disease of… 
2004
2004
Macrophage Inhibitor, Semapimod, Reduces Tumor Necrosis Factor-Alpha in Myocardium in a Rat Model of Ischemic Heart Failure
Pharmaceutical agents aimed at reducing tumor necrosis factor-alpha (TNF-α) levels appeared to be attractive possibilities in the… 
2004
2004
Screening Assay for the Identification of Deoxyhypusine Synthase Inhibitors
The 1st step in the posttranslational hypusine [Nε-(4-amino-2-hydroxybutyl)lysine] modification of eukaryotic translation… 
Review
2003
Review
2003
Semapimod. Cytokine.
Cytokine PharmaSciences is developing semapimod (CNI-1493), a cytokine inhibitor and synthetic guanylhydrazone mitogen-activated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)